SpectraCure (SPEC) Q1 2026 earnings summary

Executive summary

• Focused on advancing two clinical studies for prostate cancer using a novel photodynamic therapy (PDT) system, Q-PRO®, with promising results in both recurrent and primary localized prostate cancer studies.

• Expanded clinical trial sites, particularly in Europe, to improve patient recruitment and broaden geographic presence.

• Secured SEK 15.6 million in new funding through the exercise of warrants, supporting ongoing clinical development.

Financial highlights

• Net loss after tax for Q1 2026 was SEK -6.1 million, a slight improvement from SEK -6.3 million in Q1 2025.

• Operating result for Q1 2026 was SEK -6.1 million, compared to SEK -6.2 million in Q1 2025.

• Cash flow from operating activities was SEK -4.8 million, improved from SEK -5.6 million year-over-year.

• Cash and cash equivalents at March 31, 2026, totaled SEK 16.6 million, up from SEK 8.1 million a year earlier.

• Equity at period end was SEK 100.4 million, with a solid equity ratio of 90%.

Outlook and guidance

• Aims to complete phase 2 of the recurrent prostate cancer study and progress toward phase 3.

• Plans to increase patient recruitment and expand clinical evidence for both ongoing studies throughout 2026.

• Current liquidity is expected to cover operations into Q3 2026; additional financing is likely required before summer.